Global Antibody Drug Conjugates Market Driven by Extensive Research and Development Activities
A report from Transparency
Market Research, titled ‘Antibody Drug Conjugates Market - Global Industry
Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020,’ states that
the global antibody drug conjugates market is currently in an infancy stage and
is expected to expand at a rapid pace during the period between 2014 and 2020
due to advancements in research and development in the discovery of antibody
drugs.
Browse
Full Report : http://www.transparencymarketresearch.com/antibody-drug-conjugates-market.html
Antibody drug conjugates
are monoclonal antibodies that are attached with biologically active drugs. The
combination of cytotoxic drugs and the targeting capacity of molecular
antibodies allows antibody drug conjugates to perform targeted therapy to treat
cancer patients. This allows a sensitive discrimination between cancerous
tissues and healthy tissues. As the global antibody drug conjugates market is
in an infancy stage, only three antibody drug conjugates have received market
approval from the United States Food and Drug Administration (FDA).
The first among the three,
Mylotarg, was withdrawn from the global market by its manufacturer, Wyeth,
Inc., a company of Pfizer, Inc., in June 2010. Mylotarg was primarily used for
treating acute myelogenous leukemia. Thus, by drug, the global antibody drug
conjugates market is now classified into Kadcyla and Adcertis.
Adcertis (Brentuximab
vedotin) is a special antibody drug conjugate that is directed towards the CD30
protein and is expressed in systemic anaplastic large cell lymphoma and Hodgkin
lymphoma. Seattle Genetics, in Feb 2011, submitted a Biologics License
Application to the United States FDA for use in refractory Hodgkin lymphoma and
relapsed anaplastic large cell lymphoma. The drug received accelerated approval
from the United States FDA in August 2011. Adcertis led the global antibody
drug conjugates market during the period between August 2011 and February 2013.
In October 2012, Adcertis received marketing authorization from the European
Medicines Agency.
Kadcyla (Trastuzumab
emtansine) is an antibody drug conjugate that consists of the monoclonal
antibody trastuzumab and is linked to cytotoxic agent mertansine DM1. In Italy,
clinical trials on women suffering from HER2 positive breast cancer showed that
Kadcyla improved their survival by 5.8 months. Due to this, Kadcyla received
approval from the United States FDA in February 2013. Kadcyla, developed by
Genentech, Inc., a subsidiary of F. Hoffmann-La Roche AG, is manufactured by
Lonza group. The introduction of Kadcyla boosted the growth of the global
antibody drug conjugates market during the period between 2012 and 2013.
Request
A Sample Of This Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3858
By geography,
the global antibody drug conjugates market is divided into Asia Pacific, North
America, Europe, and Rest of the World. Most antibody drug conjugates in the
development phase are for oncological indications and are propelled by the easy
availability of monoclonal antibodies that target various types of cancer. At present,
leading players in the global antibody drug conjugates market are targeting
different domains other than oncology to develop antibody drug conjugates.
The high cost
involved in the research and development activities to discover new antibody
drugs is expected to restrict the growth of the global antibody drug conjugates
market in the years to come. Biotest Pharmaceuticals Corporation, Synthon BV,
Bayer AG, and Immunomedics, Inc. are some of the leading companies in the
global antibody drug conjugates market.
About
Us
Transparency
Market Research (TMR) is a global market intelligence company providing
business information reports and services. The company’s exclusive blend of
quantitative forecasting and trend analysis provides forward-looking insight
for thousands of decision makers. TMR’s experienced team of analysts,
researchers, and consultants use proprietary data sources and various tools and
techniques to gather and analyze information.
TMR’s data
repository is continuously updated and revised by a team of research experts so
that it always reflects the latest trends and information. With extensive
research and analysis capabilities, Transparency Market Research employs
rigorous primary and secondary research techniques to develop distinctive data
sets and research material for business reports.
Contact us:
Mr. Sudip S
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email:Â sales@transparencymarketresearch.com
Comments